MedTrace Logo

Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study

NCT06649643 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-10-21

No results posted yet for this study

Summary

Aim of Study The aim of this study to describe the clinical profile of children diagnosed as IEIs who were admitted to in Assiut university children\'s Hospital.

Conditions

  • Primary Immunodeficiency Diseases (PID)

Interventions

DIAGNOSTIC_TEST

Inborn errors of immunity

A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4\. Inflamatory marker ESR, CRP B.Immunology 1. Immunoglobulins IgG, IgM, IgA, IgE 2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM) 3. Chest x-ray to assess thymus and any abnormality 4. DHR123 whenever needed (e.g. chronic granulomatous disease). 5. LAD panel (CD11b CD15-CD18) whenever needed. 6\. Complement assay (CH

DIAGNOSTIC_TEST

A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4. Inflamatory marker ESR, CRP B.Immunology 1-Immunoglobulins IgG, IgM, IgA, IgE 2-Flow cytometric assessment: B

A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4\. Inflamatory marker ESR, CRP B.Immunology 1. Immunoglobulins IgG, IgM, IgA, IgE 2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM) 3. Chest x-ray to assess thymus and any abnormality 4. DHR123 whenever needed (e.g. chronic granulomatous disease). 5. LAD panel (CD11b CD15-CD18) whenever needed. 6\. Complement assay (CH

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-05
Primary Completion
2026-01-05
Completion
2026-03-05

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06649643 on ClinicalTrials.gov